Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1Diana Cortés‐Selva, Raluca Verona, Tatiana Perova et al.|Blood|2022Cited by 46
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Saad Z. Usmani, Niels WCJ van de Donk et al.|Future Oncology|2023Cited by 2